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DISSERTATION ABSTRACT 
There are currently more than 300 000 children under the age of 15 living with HIV in South 
Africa (SA). Due to a combination of recent success in preventing new vertical infections and 
success of paediatric antiretroviral treatment (ART) programmes in improving life-expectancy 
in perinatally HIV-infected (PHIV) children, the burden of paediatric HIV in SA has changed to 
older children. An increasing population of PHIV children on ART is reaching adolescence, yet 
information on long-term treatment outcomes in this group is lacking. There is very limited 
published data on treatment outcomes in PHIV children after ≥10 years on ART in high income 
countries (HIC), and none in low and middle income countries (LMIC). 
We conducted a retrospective cohort study of PHIV adolescents on ART for ≥10 years at a 
single ART facility. The main objective of the study was to describe long-term clinical, growth, 
immunologic and virologic outcomes in the cohort. 
Part A, the protocol, as submitted for departmental and ethical approval, details the purpose 
and methodology of the study.  
Part B, the literature review, discusses what is known about long-term treatment outcomes 
in PHIV children on ART to date. It compares findings between HIC and LMIC. Long-term 
growth, immunologic and virologic outcomes, as well as factors associated with viral failure 
are described. The paucity of long-term data is demonstrated, indicating the need for further 
research on the topic. 
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Part C, the journal-ready manuscript, details the methodology, results and interpretation of 
the longitudinal analysis of long-term treatment outcomes among 127 PHIV-infected 
adolescents and young adults on ART for ≥10 years. After median follow-up of 12 years since 
ART initiation, 80% of the cohort were virally suppressed and 79% had optimal immunologic 
status (CD4 >500 cells/µl). These results are favourable overall, but >40% of adolescents were 
on 2nd-line ART with poorer immunologic outcomes than those on 1st-line ART, and 
approximately one in three children experienced viral failure during adolescence. This 
highlights the vulnerability of this group, which requires careful further management. 
 
Appendices include all supporting documentation necessary for the above parts of the mini-
dissertation. 
 
References in Part A are in Harvard UCT style, as per the original protocol. The Vancouver 
referencing style has been used for Part B and C, in keeping with the instructions for authors 
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PART A: PROTOCOL 
 
1. Purpose of the Study 
 
 The goal of the study is to examine the long-term outcomes of antiretroviral therapy 
(ART) in perinatally Human Immunodeficiency Virus-infected (PHIV) adolescents and 
young adults. 
 The primary objectives are to measure viral suppression (viral load/VL) and 
immunologic status (CD4 results) in PHIV adolescents (age 10-19) and young adults 
(age 15-24) in an urban setting after 10 years or longer on ART. 
 The secondary objectives are to describe:  
a) ART regimens used in the cohort (names of drugs, classes of drugs and duration 
of regimens used)  
b) results of resistance testing if performed 
c) growth parameters (heights and weights) 
d) history of opportunistic infections and hospital admissions 
 The study hypothesis, based on available literature, is that after a mean period of 
follow-up on ART for 10 years or longer, approximately 50% of patients will be virally 














There are currently an estimated 340 000 children under the age of 15 living with HIV in South 
Africa (SA) (UNAIDS, 2014). Due to a combination of recent success in preventing new vertical 
infections and success of paediatric ART programmes in improving life-expectancy in PHIV 
children, the burden of paediatric HIV in SA has changed to older children and this effect is 
projected to increase further by 2020 (Johnson et al., 2012). There is an increasing population 
of PHIV children reaching adolescence in SA’s health care system, yet information on long-
term treatment outcomes in this unique group of highly treatment-experienced adolescents 
is very limited. Adolescents are at high risk of poor adherence, drug resistance and viral failure 
(VF). Barriers to adherence can include busy lifestyles, treatment fatigue, high pill burdens, 
complex twice-daily regimens, drug side-effects and disclosure issues (Fairlie, 2014). In 
addition, socioeconomic difficulties related to orphanhood and stigma, as well as HIV-related 
behavioural and neurocognitive consequences can adversely affect adolescent adherence 
(Sohn & Hazra, 2013).  
 
When VF occurs, there are limited second- and third-line ART options available in SA, 
particularly when protease inhibitors (PIs) have been used in the first-line regimen in children. 
Since national roll-out of ART started in SA in 2004, PI-based first-line therapy has been 
recommended for all children starting treatment at <3 years of age. Further therapeutic 
challenges arise in children who have failed prevention of mother-to-child transmission 
(PMTCT) with exposure to non-nucleoside reverse transcriptase inhibitors (NNRTIs) (Frigati, 
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2014), as access to alternative ART options, for example integrase inhibitors and newer PIs, 
can be challenging in SA. 
 
2.2 Studies of treatment outcomes in high income countries 
 
In high income countries (HIC), the introduction of effective combined ART in 1996 has 
resulted in the face of HIV changing to a chronic illness. Many PHIV children have become 
adolescents and subsequently transitioned to adult care. While several studies have reported 
on virologic and immunologic outcomes in PHIV cohorts on ART (see Table 1), very few have 
reported outcomes after more than a decade of treatment. Dollfus et al. (2010) followed up 
the French Perinatal Cohort of PHIV children born between 1985 and the end of 1993. Out of 
348 children, 210 (60%) remained in care after 15 years median follow-up since birth. In this 
cohort, viral suppression (VL <500 copies/ml) was achieved in 56% and optimal immune status 
in 59%. The mean number of triple ART regimens used was 2.5. The most recent regimens 
used included PIs (75%), NNRTIs (31%) or both PIs and NNRTIs (11%). De Mulder et al. (2012) 
reported on a Spanish cohort of 112 PHIV children who had 16 years median follow-up, with 
analysis performed at the time of transfer to adult care. VL ≤500 copies/ml were reported in 
56% and optimal immune status was recorded in 55%. The mean number of ART regimens 
used was 5, with 48% having used at least 3 regimens and 64% having triple class experience. 
Resistance prevalence was high in the 58 patients who had genotype resistance testing results 
available. Resistance was 51% for PIs, 77% for nucleoside reverse transcriptase inhibitors 
(NRTIs) and 37% for NNRTIs. 17% had triple resistance mutations and 81% had resistance to 
at least one drug class. The results from these 2 studies, with long follow-up periods, show 
disappointing virologic and immunologic outcomes, although they may not be generalizable 
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to SA. Many children in HIC cohorts were exposed to older, less efficacious regimens in the 
1990’s, and may therefore be at higher risk of acquired drug resistance mutations and VF than 
children in SA who generally started treatment with effective combination regimens. On the 
other hand, children in HIC cohorts have had the benefit of access to a wider range of 
antiretrovirals than children in low and middle income countries (LMIC), which may improve 
their outcomes.  
 
2.3 Studies in low and middle income countries other than South Africa 
 
Two systematic reviews of paediatric ART outcomes in LMIC highlight the paucity of long-term 
data. Sutcliffe et al. (2008) in a review on the effectiveness of ART in children in sub-Saharan 
Africa, found viral suppression was achieved in 32 – 67% of children at 36 months after ART 
start. A second systematic review of ART outcomes in children in LMIC compared with HIC 
reported favourable and comparable increases in CD4% and declines in VL, although the 
results reported were after only 12 months (Peacock-Villada, Richardson & John-Stewart, 
2011). A review exploring viral resistance in children failing first-line regimens in LMIC found 
resistance rates of 88% for NNRTIs, 80% for NRTIs, and 54% for PIs – similar to those in 
European settings (Sigaloff et al. 2011). Overall, resistance-associated mutations were found 
in 90% of children who had failed first-line ART, and the risk of resistance was found to 
increase with increased ART duration. Resistance to ART drugs is particularly concerning in 






2.4 South African studies 
 
The SA national ART programme commenced in 2004. Some sites delivered ART before this, 
funded by non-governmental organisations (NGOs). Despite the rapid scaling-up of ART 
programmes in SA over the last decade, there is very little information on the long-term 
outcomes in children on ART in SA. A few studies have reported the outcomes after 1 – 3 years 
(see Table 2). Davies et al. (2009) reported on a collaborative cohort at 7 sites of 6078 children 
who, after 3 years on ART, achieved viral suppression (VL <400 copies/ml) in 82% and a 
median CD4% of 30%. In 5485 children from the same sites, Davies et al. (2011) estimated a 
19% probability of VF (confirmed VL >1000 copies/ml) and a 6% probability of changing to 
second-line ART by 3 years. Morsheimer et al. (2014) followed-up a cohort of 613 children for 
a median 28 months. They reported that 85% achieved viral suppression (VL <400 copies/ml), 
while CD4% reached a mean of 17% after 3 years.  
 
2.5 Study rationale 
 
Although these figures of above 80% for viral suppression in SA cohorts are encouraging, the 
follow-up time in these studies is limited. Longer durations on ART, in conjunction with sub-
optimal adherence and accumulation of resistance mutations, may be expected to lead to 
declines in viral suppression. Although national paediatric ART programmes were 
implemented in SA over a decade ago, the long-term outcomes of PHIV children on ART have 
not yet been examined. Describing the ART history and outcomes in this treatment-
experienced population may help clinicians to anticipate future therapeutic challenges and 
plan ahead. Insight into the prevalence of viral suppression, VF, viral resistance and immune 
reconstitution may provide important information to guide health care providers in the 
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management of this group, before, during and after their transition to adult care. This study 
aims to provide information on long-term outcomes in South Africa, which can contribute 




3.1 Study design 
 
 The study is a descriptive, retrospective cohort study of PHIV adolescents and young 
adults on ART.  
 The expected duration of the study will be approximately 2 years (Table 3), although 
since this is a retrospective study, the actual follow-up data that will be collected will 
be for considerably longer. 
 Primary outcome variables are VL and CD4 results.  
 Secondary outcome variables:  
a) ART regimen history (drug names, class, formulations, duration of regimens and 
reasons for drug changes)  
b) Results of resistance testing (if performed) 
c) Clinic visit dates with corresponding height and weight measurements 
d) History of opportunistic infections and hospital admissions 
 
3.2 Study population 
 
The study population consists of PHIV adolescents and young adults attending the Adolescent 
Infectious Diseases Clinic at Groote Schuur Hospital (GSH) in Cape Town. This is a tertiary-
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level clinic in an urban setting. The ART programme was initially funded and implemented by 
a NGO (Kidzpositive) in 2002, and was taken over by the Department of Health during 2004.  
 
3.3 Inclusion and exclusion criteria 
 
Inclusion criteria for study participants: 
 ART initiation at the GSH out-patient clinic  
 Alternatively, ART initiation in the GSH paediatric ward as an in-patient, provided 
follow-up care occurred at the GSH clinic  
 age <12 years at ART initiation (the maximum age at the time for referral to the 
paediatric services; also serves as a proxy for perinatal route of infection) 
 ART initiated between 13 May 2002 (inception of the ART programme)  and 31 
December 2005 
 Attendance at the GSH clinic for a minimum of 10 years from ART initiation date 
 Previously ART-naïve, with the exception of possible nevirapine exposure as part of 
the PMTCT programme which was implemented from 1999 in the Western Cape 
(Johnson, 2009:2) 
 Children who initiated care at the clinic as part of a clinical research study will be 
included, provided that the study was a pharmacokinetic study and not a study 
comparing the effectiveness of different antiretroviral treatments or other 
interventions 
Exclusion criteria: those who were not in care at the clinic at least 10 years after ART initiation, 




3.4 Expected number of participants 
 
Participants will be identified from the clinic’s enrolment register and attendance database. 
A preliminary assessment shows that 354 children enrolled for ART initiation between 13 May 
2002 and 31 December 2005. Of these, 29 (8%) died, 52 (15%) were LTFU and 147 (42%) were 
transferred to another facility. The remaining 126 (35%) remain in active care and will form 
the cohort for the study. These figures are estimates; the eligibility of each participant will be 
assessed when the medical records are reviewed. A sample size calculation is shown in Box 1.  
 
3.5 Study procedures and data collection methods 
 
The required clinical data will be collected retrospectively by the study researcher (Kim 
Anderson), from the patients’ medical records stored in the clinic. Information will be 
captured from the time of ART initiation up until and including 31 December 2015. The 
following information will be extracted from the records:  
 date of birth 
 gender 
 PMTCT antiretroviral history 
 ART regimen used at initiation (drug names and formulations) 
 any drug changes made thereafter, with corresponding dates and reasons for changes 
 resistance test results if performed 
 CD4 results at ART initiation (absolute counts and percentages), and all subsequent 
CD4 results 
 all available VL results (absolute values and log values)  
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 clinic visit dates 
 growth measurements: heights and weights 
 history of opportunistic infections and hospital admissions 
 
CD4 and VL tests were performed by the National Health Laboratory Service (NHLS), which is 
the public laboratory service provider in SA. Laboratory results will be checked on the NHLS 
database. The researcher will manually enter all the data directly onto prepared data sheets 
(appendix 2). The data sheets will not contain any patients’ names, only an allocated study 
number. At a later stage, the data will be captured electronically and analysed. The research 
findings will be submitted to an appropriate journal for publication, most likely the South 
African Medical Journal or PloS One.  
 
3.6 Data safety 
 
The data sheets will not contain any patients’ names, only an allocated study number. The 
collected data (manual and electronic) will be stored in a locked clinic office, accessible only 
by the researcher and 2 other clinic doctors. The list of patients’ names linking them to their 
allocated study number will be kept in a locked cabinet in a locked office, separate from other 
study documentation and accessible only by the study researcher. Electronic data will be 
stored anonymously on the researcher’s password-protected laptop computer. This will be 
kept on her person at all times during the day, and securely locked in her home at night. 





3.7 Data analysis 
 
Continuous and categorical variables will be summarised using medians and interquartile 
ranges and proportions respectively. The primary outcomes, VL and CD4 trajectories, and 
factors associated with different trajectories, will be examined using survival analysis. Cox 
modelling will be used to examine probability of VF and predictors of VF, with variables for 
inclusion in the models selected a priori. Statistical analysis will be performed using Stata 14.0. 
 
3.8 Definitions  
 
 Viral suppression will be regarded as VL < 400 copies/ml  
 Viral failure will be defined as two sequential VL > 1000 copies/ml that were taken 
between 14-365 days apart and were not measured during a treatment interruption 
 CD4 results will be recorded as both absolute counts and percentages. WHO (2007) 
age-related classification of immunosuppression will be used (see appendix 3) 
 Opportunistic infections characteristic of stage 3 and 4 HIV infection will be recorded 
(see appendix 4) 
 Changing from first- to second-line therapy will be defined as changing at least 2 ART 
drugs in the regimen, one of which is a class switch from NNRTI to PI or PI to NNRTI, 
where the reason for changing drugs is not documented to be toxicity and the child 
was not virally suppressed at the time of switch 
 When genotypic resistance data is available, it is reported as predicting low, 
intermediate or high level resistance to specific ART drugs. Drug resistance will be 
defined as intermediate- or high-level resistance 
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 LTFU will be is defined as when the last visit was >6 months before database closure 
in a child not known to have transferred out or died 
 
4. Strengths and limitations 
 
 Strengths of the study include the long follow-up period and that it will reflect real-
world examples rather than trial settings. The extended time frame will allow for some 
patients to be included who might have previous gaps in care and might have been 
considered LTFU at an earlier stage, as some patients cycle in and out of care.  
 Limitations of the study include the small study size, the retrospective study design and 
that the data comes from a single study site in a tertiary institution. In addition, since the 
study focuses on children on ART for at least 10 years at the same site, there is a survival 
bias in this cohort. Nevertheless, it is precisely this surviving group of PHIV adolescents 
that one wants to describe in order to improve their management during adolescence 
and transition to adulthood.  Selection bias is a factor through LTFU among participants. 
There may be reduced external validity due to the fact that this is a tertiary care cohort, 
and that within SA the model of retaining children at a separate paediatric tertiary facility 
is unusual. Also, the children who have accumulated 10 years of follow up are those who 
started earlier in the ART programme, many of whom might have been generally known 
to the clinic and adherent before ART became widely available, and are therefore 
possibly different to children who started later in the programme. Some variables that 
may be related to the risk of developing VF (e.g. caregiver factors, disclosure, depression, 







 Ethical review: The study protocol, data collection tools and other requested 
documents will be submitted for review and approval by the University of Cape Town’s 
Faculty of Health Sciences Human Research Ethics Committee (HREC). 
 Risks: There is minimal risk to participants due to the nature of the study. There will 
be no direct contact with participants during the data collection process; all data will 
be gathered by retrospective review of medical records. The risk of loss of 
confidentiality will be minimised by keeping the captured data anonymous and storing 
data safely as described. Personal and sensitive information may be viewed in the 
patients’ folders during the course of data extraction, but as the researcher who will 
collect the data currently works as a doctor at the clinic, it would fall within the scope 
of her daily work to access this type of information when consulting with patients, 
whilst maintaining patient confidentiality. The researcher has received training on 
issues of confidentiality (Good Clinical Practice training course completed in SA, and 
the National Institutes of Health “Protecting Human Research Participants” course) 
and will ensure every effort is made to maintain confidentiality. 
 Benefits: There will be no direct benefits to the participants of the study, however the 
knowledge gained from the study will contribute to knowledge of treatment outcomes 
in adolescents and young adults with PHIV. This will help to optimise the management 
of PHIV adolescents and may help motivate for better second- and third–line 
treatments to be made available. Managers of the GSH clinic and the populations 
served by the clinic stand to benefit from the knowledge gained, as well as other 
programmes managing PHIV adolescents in the region. 
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 Confidentiality: The data sheets will not contain any patients’ names, only an 
allocated study number. Data will be stored anonymously in a locked clinic office. The 
list of patients’ names linking them to their study number will be kept in a locked 
cabinet in a locked office, separate from other study documentation and accessible 
only by the study researcher, in order to achieve a higher level of privacy. Data will be 
stored for 2 years after publication, after which time: all paper documents will be 
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Table 1: Studies of long-term outcomes in perinatally-HIV-infected children receiving 
antiretroviral therapy in countries other than South Africa 
 
















line ART or 
beyond 
Patel et al.  
(2008) 
USA 1236 3 NR 36-59% 
 
NR 
Dow et al.  
(2014) 
Tanzania 161 4 73% NR 41% 
Bunupuradah et al.  
(2015) 
Thailand 840 6 68% 69% NR 
Chokephaibulkit et al.  
(2014) 
Asia 1061 6 68% 70% 15% 
Cruz et al.  
(2014) 
Brazil 260 7 57% NR 63% 
Souza et al.  
(2010) 
Brazil 49   9 * 53% 82% NR 
Dollfus et al.  
(2010) 
France 210 15 56% 59% NR 
De Mulder et al.  
(2012) 
Spain 112 16 56% 55% 64% 
 
Abbreviations: ART=antiretroviral therapy; USA=United States of America; NR=not reported.        *mean 
 
 
Table 2: Studies of outcomes in perinatally-HIV-infected children receiving antiretroviral therapy 
in South Africa 
 







CD4% Proportion on 
second-line ART 
or beyond 
Porter et al. 
(2015) 




56% NR NR 
Davies et al. 
(2009) 







Davies et al. 
(2011) 




NR NR 6% 
probability 
Morsheimer et al. 
(2014) 













Table 3: Gantt chart of project management 
 
 





























































































































































































Viral suppression is the primary outcome, and the hypothesis is that viral suppression will be 
found in 50% of cases. There will be approximately 100 children on the study, with at least 1 
viral load in the adolescent period (or after 10 years on ART). In order to detect if it is much 
higher than 50%, say 65%: 
Stata command: sampsi 0.5 0.65, n1(100) onesample 
Output: Estimated power for one-sample comparison of proportion,  to hypothesized value 
Test Ho: p = 0.5000, where p is the proportion in the population 
 
Assumptions:  alpha = 0.05  (two-sided) 
alternative p =  0.65 
sample size n = 100 
 
Estimated power: power = 0.8622 
So a sample of at least 100 children will have at least 85% power to detect if the proportion 
of children with viral suppression is at least 15 percentage points more than 50% with 
significance of 0.05. 
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There are currently an estimated 320 000 children under the age of 15 living with HIV in South 
Africa.[1] Due to a combination of recent success in preventing new vertical infections and success 
of paediatric ART programmes in improving life-expectancy in PHIV children, the burden of paediatric 
HIV in SA has changed to older children. This effect is projected to increase further by 2020 as PHIV 
children age into late adolescence.[2] Information on long-term treatment outcomes (including 
virologic, immunologic and growth outcomes) in this unique group of highly treatment-experienced 
adolescents in SA is very limited. Adolescence in general is a period characterised by physical, 
emotional and psychological change. It is associated with developing autonomy and sexuality, 
questioning authority, greater peer influence, increased impulsivity and risk taking.[3] Adolescents 
with HIV are at high risk of poor ART adherence, drug resistance and viral failure. Barriers to 
adherence can include the normal psychosocial changes of adolescence, busy schedules (school and 
social), treatment fatigue, high pill burdens, complex twice-daily regimens, drug side-effects and 
disclosure issues.[3] Youths reported “forgetting, not feeling like taking medication and not wanting 
to be reminded of HIV infection”[4] as common barriers to ART adherence. In addition, 
socioeconomic difficulties related to orphanhood and stigma, as well as HIV-related behavioural and 
neurocognitive consequences can adversely affect adolescent adherence.[5]  
 
Although there is an increasing population of PHIV children on ART reaching adolescence and young 
adulthood, healthcare systems are often lacking in preparedness to deal with their complex and 
evolving needs. Psychosocial support services can significantly improve outcomes in these youths, 
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but in Africa HIV services dedicated to young people and their needs are scarce.[6] Mark et al.[7] 
surveyed HIV services for adolescents in sub-Saharan African countries and found that almost two-
thirds attended to adolescents together with adults and/or children, and half had no protocols for 
transitioning adolescents. Globally, more research is needed to investigate transition practices from 
childhood to adolescent care and adolescent to adult care.[8] 
 
In addition to healthcare system limitations, there are treatment limitations. When viral failure 
occurs, there are restricted second- and third-line ART options available in SA, particularly when PIs 
have been used in the first-line regimen. Since national roll-out of ART started in SA in 2004, PI-based 
first-line therapy has been recommended for all children starting treatment at <3 years of age. 
Further therapeutic challenges arise in children who have failed PMTCT with exposure to NNRTIs.[9] 
Access to alternative ART options, for example integrase inhibitors and newer PIs, is limited in SA.  
 
To inform the proposed study of PHIV adolescents who initiated ART >10 years ago at a facility in 
South Africa, this literature review aims to describe what is known about long-term treatment 
outcomes in PHIV children on ART to date.  
 
2. Objectives of the literature review 
 
The main objective of the literature review is to examine articles that report on long-term growth, 






3. Literature search strategy 
 
Eligibility criteria for articles were systematic reviews, observational or experimental studies 
published prior to 1 January 2018, that reported on treatment outcomes in cohorts that included 
predominantly (>50%) PHIV children, adolescents or young adults treated with three-drug ART 
(mostly from at least 2 classes), or that reported separate outcomes in PHIV participants as a subset 
of a larger cohort. Studies that reported on virologic and/or immunologic outcomes were included if 
the mean/median follow-up duration was a minimum of 5 years or longer. Due to the paucity of long-
term studies in SA, studies were included if SA outcomes were reported for a minimum of 3 years.  
Similarly, due to the shortage of studies reporting growth outcomes, specifically end of study height-
for-age Z-scores (HAZ), articles were included if growth was reported for a minimum of 3 years on 
ART. If the duration of follow-up or ART was not reported, studies were included if median age of 
PHIV adolescent cohorts on ART was >10 years at analysis, as a proxy for long-term care. 
 
The literature was searched through the PubMed database using the search terms shown in Box 1. 




Box 1: Pubmed search terms used for literature  
 
4. Results of literature search 
 
I identified 34 studies that described long-term immunologic, virologic or growth outcomes (14 
studies in HIC and 20 in LMIC). Among these studies, 29 reported long-term virologic and/or 
immunologic outcomes: 14 in HIC with outcomes ≥5 years’ follow-up duration (of which 6 had ≥10 
years follow-up duration); 9 studies in LMIC other than SA with outcomes ≥5 years; and 6 studies in 
SA with outcomes ≥3 year (Table 1A-D). Ten studies reported growth outcomes ≥3 years’ follow-
up/ART duration: 1 in a HIC, 3 in SA and 6 in other LMIC (Table 2). In addition to the 34 articles that 
described long-term ART outcomes that were systematically reviewed, in order to better understand 
viral outcomes I selectively drew on articles that described resistance and factors associated with 
virologic outcomes in children and adolescents.  
 
 
(HIV infections[MeSH] OR HIV[MeSH] OR HIV OR HIV1 OR HIV2 OR Human immunodeficiency 
virus OR human immuno-deficiency virus OR human immune-deficiency virus) AND (Perinatally 
OR perinatal OR prenatal OR postnatal OR antenatal OR vertically infected) AND 
(Adolescent[MeSH] OR Child[MeSH] OR Adolescence OR adolescent OR adolescents OR 
teenagers OR teen OR youths) AND (Antiretroviral Therapy, Highly Active[MeSH] OR Anti-
Retroviral Agents[MeSH] OR Antiretroviral OR anti-retroviral OR antiviral OR anti-HIV agents OR 
ART OR ARV OR HAART) 
 
in combination with the following terms (as 2 separate searches): 
 
(i) AND (Treatment outcome[MeSH] OR Outcome OR effectiveness OR efficacy OR prognosis OR 
prognostic OR Viral load[MeSH] OR CD4 Lymphocyte Count[MeSH] OR Viral load OR CD4) 
 
(ii) AND (Human Development[MeSH] AND Body Size[MeSH] AND Growth OR development OR 





5. Long-term virologic and immunologic outcomes in high income countries  
 
The introduction of effective combined ART from 1996 in HIC resulted in the face of HIV slowly 
changing to a chronic illness. Many PHIV children have aged up to adolescence and beyond, and 
transitioned to adult care. There were 14 studies reporting virologic and immunologic outcomes from 
HIC: 7 from the US,[10–16] 1 from Canada,[17] 2 from the UK and Ireland [18,19] and 4 from other 
European countries.[20–23] Although several studies reported viral and immunological outcomes in 
PHIV cohorts on ART, very few (n=6) reported outcomes after more than a decade of treatment 
(Table 1A).  
 
The six studies that reported outcomes after ≥10 years, had median duration of patient follow-up of 
11 – 16 years (which was not necessarily the duration since ART start). Sample size varied from 112 
– 654 patients. Median age at ART start varied from 6 – 10 years in 5 studies, but was <1 year in one 
US study. Median age at analysis was 12 – 19 years. Median/mean CD4 at study endpoints ranged 
from 444 – 720 cells/µl, while percentage with optimal immune status (defined in all studies as CD4 
count >500 cells/µl in those age ≥ 5 years) ranged from 42 – 59%. Viral suppression at study endpoints 
was fairly poor, varying from 37 – 57% in 4 studies. Viral suppression was higher in a US study (68%) 
which had a much younger median age at ART start (<1 year), and better results were reported in a 
UK cohort (78% of those on ART were virally suppressed), but only 61% of the cohort were on ART. 
Cohorts of PHIV patients usually include patients who are not on ART, either due to delays in starting 





Given the limited number of studies available reporting outcomes after >10 years of follow-up, these 
will be described in some detail. Dollfus et al.[21] followed up the French Perinatal Cohort of PHIV 
children born between 1985 and the end of 1993. Out of 348 children, 210 (60%) remained in care 
after a median 15 years of follow-up since birth. In this cohort, at the most recent evaluation, viral 
suppression (VL <500 copies/ml) was achieved in 56% and optimal immune status in 59%. The most 
recent regimens used included PIs (75%), NNRTIs (31%) or both PIs and NNRTIs (11%).  
 
Two studies described cohorts at the time of transfer to adult care.[18,20] De Mulder et al. reported 
on a Spanish cohort of 112 PHIV children who were followed-up for a median 15.6 years. VL was ≤500 
copies/ml in 56% and optimal immune status was recorded in 55%. The lifetime mean number of ART 
regimens used was 5, with 64% having triple class experience. Collins et al. reported on the outcomes 
of 644 adolescents (91% PHIV) in the UK and Ireland. Median duration of follow-up in paediatric care 
was 10.9 years and median duration since ART initiation was 7.8 years. Median CD4 was 444 cells/µl 
and 42% had optimal immune status. Overall, 57% of patients were virally suppressed (VL <400 
copies/ml) at transfer, whereas 74% of those on ART at transfer (357/481) were virally suppressed.  
 
In the US, Van Dyke et al.[11] reported better outcomes in 451 PHIV children and adolescents from 
multiple sites where median duration of ART was 11.4 years and median age at ART start was younger 
(< 1 year) than in the European studies. At last assessment, median CD4 count was 728 cells/µl, 78% 
had a CD4% ≥ 25% and viral suppression occurred in 68% of the cohort (VL ≤ 400 copies/ml).  In 
another US study, worse outcomes were reported by Kahana et al.[10]  in a cross-sectional cohort of 
649 older PHIV youths (median age 18 years vs 12 in Van Dyke study) with a similar median follow-





Among the 8 studies with <10 years or unreported follow-up duration, only 4 studies included >50 
participants (Table 1B).Median/mean age at study ranged from 15 - 26 years and the proportion 
virally suppressed was generally low, ranging from 31 - 65%, except for one small Swedish transitional 
study which was higher.[22] 
 
Among those in cohorts who had resistance test results available (34 – 52% of individual cohorts), 
resistance prevalence was high, ranging from 73 – 82% resistance to at least one drug class and triple 
class resistance in 12 – 17%.[18,20,24,25] However, a large proportion of youths in these studies 
(65% in one US study [24]) may have received single or dual antiretrovirals before receiving 
combination ART, increasing their risk of acquiring resistance mutations. Judd et al.[26] found a high 
risk of triple class VF in PHIV European teenagers age 10 – 14 years (nearly 30% after 5 years on ART), 
highlighting the vulnerability of this age group, while a UK study observed declines in CD4s prior to 
adult care transition, which was considered a possible reflection of growing autonomy and worse 
adherence during adolescence.[27] 
 
Results describing PHIV cohorts in HIC are limited and demonstrate generally poor outcomes. 
However, these results may not be generalizable to LMIC, including South Africa, as many children in 
the HIC cohorts were on the one hand exposed to older, less efficacious regimens in the 1990s, while 
on the other hand they were likely to have had access to a wider range of antiretrovirals and more 





6. Long-term virologic and immunologic outcomes in low and middle income countries other than 
South Africa 
 
There is no published data on treatment outcomes in LMIC for 10 years or longer. This may be due 
to delays in the roll-out of ART programmes in LMIC, with limited numbers of survivors of paediatric 
HIV beyond 10 years of age and limited access to laboratory testing in ART patients. A survey of HIV 
treatment services for adolescents in 218 facilities in 23 sub-Saharan African countries found that VL 
was monitored in less than half of facilities.[8] The key challenges in adolescent service provision 
reported by the facilities surveyed were treatment failure and non-adherence. If children and 
adolescents are seen together with adults in integrated clinics they may be less easy to monitor as a 
distinct group, while movement of patients between facilities may also hamper efforts to track long-
term outcomes.  
 
There were 9 studies reporting virologic and immunologic outcomes after ≥5 years of follow-up from 
LMIC other than SA (3 in South East Asia,[28–30] 3 in Brazil [31–33] and 3 in Africa [34–36]), with 
outcomes reported between 5 – 9 years follow-up duration (see Table 1C). Sample size varied from 
49 – 1061 patients. Median age at ART start varied from 4 – 9 years, similar to most of the HIC studies, 
whereas median age at analysis was younger (9 – 15 years) due to shorter follow-up duration. 
Median/mean CD4 at study endpoints ranged from 622 – 829 cells/µl, while percentage with optimal 
immune status ranged from 69 – 82%. Viral suppression at study endpoints varied between 53 – 68%. 
These immunologic and virologic outcomes were better than those reported in HIC studies of longer 
duration, most likely because of shorter follow-up durations. Declining outcomes with increasing 




Systematic reviews of paediatric ART outcomes highlight the paucity of data on long term outcomes. 
Sutcliffe et al.[37] in a review on the effectiveness of ART in children in sub-Saharan Africa, found 
viral suppression was achieved in 47 – 83% of children at 3 years after ART start, and that 71 – 85% 
of children with resistance to at least one class of drugs failed to achieve viral suppression. A 
systematic review of outcomes of ART in children in LMIC compared with HIC reported favourable 
and comparable increases in CD4% and declines in VL, although the results reported were after only 
12 months and mean baseline CD4% in LMIC vs HIC was 12% compared with 23%.[38] Starting ART 
with differing disease severity makes global comparisons of treatment outcomes difficult. Similarly, 
Davies et al.[39] in a review of published clinical studies on paediatric ART programmes in sub-
Saharan Africa found that although virologic and immunologic outcomes were comparable with HIC, 
the duration of follow-up was mostly limited to one year.  
 
A review exploring viral resistance in children failing first-line regimens in LMIC (mostly in sub-
Saharan Africa) found resistance rates of 88% for NNRTIs, 80% for NRTIs, and 54% for PIs – similar to 
those reported in European settings.[40] Overall, resistance-associated mutations were found in 90% 
of children who had failed first-line ART. The risk of resistance was observed to increase with 
increased ART duration. High prevalence of multi-drug resistance has been seen in both HIC and 
LMICs.[41] Increased implementation of PMTCT measures may account for higher prevalence of 
NNRTI resistance in some studies. Jordan et al.[42] found high rates of NNRTI resistance (53%) pre-
treatment in children in sub-Saharan African countries exposed to NNRTIs through PMTCT. 
 
In a recent cohort of 125 PHIV children and adolescents failing ART in Togo, the proportion with drug 
resistance mutations was high (94%), largely due to resistance to both NRTIs and NNRTIs (88%).[43] 
Similar findings were observed in a Tanzanian study of 213 children. Among those with VF (25%), 
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drug resistance mutations were found in 90%, while multi-class resistance occurred in nearly 
80%.[44] Such high rates of resistance are concerning, particularly in LMIC where access to 
alternative drugs is very limited. 
 
7. Long-term virologic and immunologic outcomes in South Africa  
 
The SA national ART programme commenced in 2004. Some sites delivered ART before this, funded 
by NGOs. Despite the rapid scaling-up of ART programmes in SA over the last decade, there is little 
local information on the long-term outcomes in PHIV children on ART. Six studies reported virologic 
and immunologic outcomes,[45–50] mostly at urban centres (see Table 1D). Outcomes were 
reported between 3 – 8 years follow-up and sample size varied from 126 – 515 children in 5 studies, 
while one collaborative cohort included 6078 patients. Median age at ART start ranged from 4 - 11 
years, similar to other LMIC and HIC studies. Median age at analysis (12 – 17 years), as well as 
immunologic and virologic outcomes, were similar to studies in other LMIC. CD4 medians at study 
endpoints ranged from 636 – 713 cells/µl, while only one study reported a percentage with optimal 
immune status (64%). Viral suppression at study endpoints varied from 69% (after 6 years median 
follow-up) to 82% (at 3 years). 
 
Davies et al.[50] reported on a large collaborative cohort  of 7 International epidemiologic Databases 
to Evaluate AIDS (IeDEA) SA sites consisting of 6078 children who, after 3 years on ART, achieved viral 
suppression (VL <400 copies/ml) in 82% and a median CD4% of 30%. These results are satisfactory, 
but the follow-up duration was very limited. In 5485 children from the same sites, a 19% probability 
of VF (confirmed VL >1000 copies/ml) and a 6% probability of changing to second-line ART by 3 years 
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was found.[51] Further analysis of the large IeDEA cohort may provide future insights, but no longer-
term outcomes have yet been published. 
 
A few smaller cohorts have reported outcomes in young adolescents after 6 – 8 years on ART. A cross-
sectional study of 474 PHIV young adolescents in Cape Town, median age 12 years and median 
duration of ART use 7.5 years, showed favourable outcomes of median CD4 count of 710 cells/µl and 
VL <50 copies/ml in 76%,[45] although this cohort was recruited during late childhood/early 
adolescence for research and is not likely to fully represent outcomes in routine care. An adherence 
study among 126 adolescents in Johannesburg, aged 12 – 20, reported viral suppression in  69% after 
6.3 median years ART duration.[49] A lower proportion of those in older adolescent categories (62% 
for 15-17 years and 68% for 18-20 years) experienced viral suppression compared to those aged 12-
14 years (74%), highlighting that older adolescents appear to be particularly vulnerable, although the 
proportion of the cohort PHIV was not recorded. A study among 241 PHIV adolescents and young 
adults in Durban with median ART duration of approximately 6 years had  better prevalence of viral 
suppression in 81%.[48]  
 
8. Factors associated with viral failure in children and adolescents 
 
In addition to ART adherence, a variety of factors have been associated with VF or elevated VL in 
PHIV children and adolescents in the literature. A number of individual socio-demographic and 
clinical factors have been reported to be associated with poor viral outcomes. Male gender was a risk 
factor in several studies,[21,45,52] although one study found female gender was a significant 
predictor.[10] In the US and France, racial or ethnic factors predicted poor viral outcomes,[10,16,21] 
but this is likely very context-specific and linked to social vulnerability. Lower CD4% at ART initiation 
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[53], lower current CD4 count,[18,21,28] lower CDC staging [18,20,52], higher VL (>1 million 
copies/ml) at ART initiation [51] and wasting [54] have been shown to predict worse virologic 
outcomes. Having preadolescent VF was a predictor of post-suppression virologic rebound (VL >1000 
copies/ml) in an Asian adolescent cohort.[54] Belonging to cohorts from earlier calendar 
periods,[10,53] younger age at ART initiation [29] and older current age [10,16,45,53,55] have been 
associated with increased risk of elevated viral load. Socioeconomic predictors include lower level of 
education,[55] living out of a main urban area [52] or being raised by grandparents.[54] 
 
Treatment-related factors associated with poor viral outcomes include previous exposure to PMTCT 
regimens,[51] previous non combination-ART,[18,53] increased number of previous ART regimens 
[10] and receiving second-line regimens.[30,54] Use of nevirapine versus lopinavir with ritonavir,[56] 
use of nevirapine versus efavirenz [51] and use of ritonavir as a single PI [51,57,58] are all associated 
with worse virologic outcomes. Both nevirapine and ritonavir (as a single PI) were commonly used as 
the “third drug” part of first-line paediatric regimen options in early treatment guidelines. Factors 
related to healthcare settings associated with elevated VL include down-referral after ART initiation 
in hospital versus starting ART in the primary healthcare system,[59] attending a standard paediatric 
clinic versus an adolescent clinic [48] and transitioning to adult care.[55] 
 
9. Growth outcomes  
  
Growth deficits are common in PHIV children and adolescents, and are associated with a variety of 
factors including malabsorption, micronutrient deficiency, impaired growth hormone production, 
symptomatic HIV infection, inflammation and viraemia.[60] Slow weight gain and height deficits 
occur frequently in PHIV children and may result in stunting and reduced final height.[61] This effect 
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has been seen more profoundly among African children compared with those in HIC,[62] and, once 
stunted, sufficient catch-up growth may not occur in order to reach normal height. In addition, long-
term ART use of particular ART drugs can lead to changes in body composition, with 30 – 70% of 
children on ART experiencing fat redistribution,[60] which may be disfiguring and stigmatising.  
 
Pubertal delay is characteristic of PHIV. Szubert et al.[63] measured height growth and Tanner staging 
in 620 adolescents in Uganda and Zimbabwe, and found a considerable delay in pubertal stages, 
associated with initiating ART at older ages. In addition, growth was observed to continue until later 
in adolescence, which may be a possible benefit to delayed puberty, as there is potential for further 
catch-up linear growth. A systematic review of growth reconstitution following ART in HIC versus 
LMIC by McGrath et al.[64] found that LMIC children were substantially shorter at ART initiation (HAZ 
−2.2 vs. −0.9), despite comparable age. Children in LMIC maintained worse height outcomes at 2 
years, despite marked improvements following ART initiation, attributed to baseline differences that 
did not recover. However, the duration of studies compared in the review were short overall. 
 
Ten studies were identified that described growth (HAZ) outcomes ≥ 3 years follow-up/ART duration 
(1 in a HIC [21]; 6 in LMIC other than SA [29,30,65–68]; and 3 in SA [47,50,69]) (see Table 2). The only 
study that reported growth outcomes after more than a decade of follow-up was a French study in 
which HAZ was normal (median -0.02) at median age of 15 years.[21] The remaining 9 studies from 
LMIC (including SA) had follow-up duration ranging from 3 – 8 years, while age at analysis varied from 
12 – 18 years (but was not reported in 6 of the studies). Median/mean HAZ at ART initiation varied 
from -3.12 to -2.2, and at study completion varied from -2.33 after 3 years on ART to -1.04 after 6 
years on ART. Despite HAZ improvements over time, in all the studies in LMIC, PHIV adolescents 
continued to be at least one standard deviation below normal height. The few studies that reported 
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on BAZ showed mean values within normal ranges, demonstrating that although stunting is common 
in PHIV children, body mass index is less severely affected. 
 
Gsponer et al.[68] examined growth response up to 3 years after starting ART in 17 990 children in 5 
Southern African countries, including SA. At ART initiation, a large proportion were underweight 
(50%) and stunted (66%). Baseline Z-scores were found to be the most important predictors of 
growth response. Bunupuradah et al.[67] analysed final heights reached in 273 PHIV Asian 
adolescents at age 18. Median HAZ at ART initiation was -2.22, which improved to -1.51 at age 18. By 
World Health Organization standards, 19% were stunted at age 18. Half of the children who were 
stunted at ART initiation remained stunted. However, most started ART late with median age at ART 
initiation of 11.4 years.  Among the largest cohort reported in SA (6078 children from different sites), 
median age at ART initiation was 3.6 years and median HAZ was -2.34.[50] Median HAZ of -1.32 was 
reported at 3 years since ART initiation but longer-term outcomes including final height have not yet 
been published for this SA cohort. 
 
10. Study rationale 
 
There is very limited information on long-term outcomes in PHIV adolescents on ART. Although some 
of the figures reported for viral suppression in PHIV cohorts in South Africa are encouraging, the 
follow-up time in these studies is limited. Longer durations on ART, in conjunction with sub-optimal 
adherence and accumulation of resistance mutations, may lead to a decline in viral suppression. 
Although national paediatric ART programmes were implemented in SA over a decade ago, the long-
term outcomes of PHIV children after ≥ 10 years on ART have not yet been reported. Describing the 
ART history and outcomes in treatment-experienced adolescents and young adults can help clinicians 
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to anticipate future therapeutic challenges and plan ahead. Insight into the prevalence of viral 
suppression, VF, viral resistance, immune reconstitution and factors associated with VF can provide 
important information to guide health care providers in the management of this group, before, 
during and after their transition to adult care. This study aims to provide information on long-term 
treatment outcomes in a cohort of PHIV adolescents on ART for ≥10 years, which can contribute 
significantly to available knowledge, and may help to optimise the future management of this group.  
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TABLE 1A: STUDIES FROM HIGH INCOME COUNTRIES WITH >10 YEARS FOLLOW-UP 


























end of study 
(IQR) 
%  with 
CD4 ≥500 
cells/µl 
% with viral 
suppression 













PC 644 10.9 9.6 17.4 NR 444 
(280 - 643) 






CS 649 11.3  
(since HIV 
diagnosis) 
NR 17.9 NR 541  
(mean) 






RC 112 15.6 5.6 18.9 NR 627  
(mean) 






RC 451 11.4 0.8 12.2 NR 728 
(530 - 966) 






PC 210 15  
(follow-up; 
since birth) 
7.5 15 NR 557 
(382 - 861) 












654 2 groups 
(11.4 and 
5.1) 
9 NR 13% 555 
(324 - 802) 







ART:antiretroviral therapy, IQR:interquartile range, VL:viral load, UK:United Kingdom, USA:United States of America, NR:not recorded, PC:prospective cohort, CS:cross-
sectional, RC:retrospective cohort 
Note: overall cohort statistics provided where available; years reported to one decimal place unless reported without a decimal in the articles 
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TABLE 1B: STUDIES FROM HIGH INCOME COUNTRIES WITH <10 YEARS FOLLOW-UP OR UNREPORTED DURATION 



























(cells/µl) at end 
of study (IQR) 




% of cohort 
with viral 
suppression at 
































CS 34 9 NR 19 NR NR NR Among the 
88% of cohort 








CS 141 7 NR 20 NR 560 
(320 - 909) 













NR 20.9 NR 580 
(325 - 822) 

























RC 49 5.0 
(mean) 
6.7 NR 14% NR NR 55% at 7 years <500 
ART:antiretroviral therapy, IQR:interquartile range, VL:viral load, USA:United States of America, NR:not recorded, PC:prospective cohort, CS:cross-sectional, 
RC:retrospective cohort, PHIV:perinatally HIV-infected   




TABLE 1C: STUDIES FROM LOW AND MIDDLE INCOME COUNTRIES EXCLUDING SOUTH AFRICA 
































% of cohort 
with viral 
suppression 















2002 - 2013 






2010 - 2012 
CS 568 5.9 9.0 14.4 NR 635  
(441 - 859) 





2005 - 2008 
RC 277 NR (5 year 
outcomes 
reported) 





2008 - 2013 
RC 840 5.6 NR NR NR 622  
(411 - 838) 









1991 - 2011 
RC 1061 6.0 8.8 14.7 7 657  
(470 - 862) 




2009 - 2011 




2008 - 2013 
CS and 
PC 
161 6.4  
(at first 
analysis) 
NR 12.2 NR 829  
(mean) 
70% 66% at first 
analysis; 







2006 - 2007 






NR 766  
(mean) 
82% 53% <400 
ART:antiretroviral therapy, IQR:interquartile range, VL:viral load, NR:not recorded, PC:prospective cohort, CS:cross-sectional, RC:retrospective cohort 






TABLE 1D: STUDIES FROM SOUTH AFRICA 































% of cohort 
with viral 
suppression 









2017 NR CS 474 7.5 4.5 12.0 NR 710 
(564 - 949) 






2017 2004 - 
2014 
RC 460 5.5 8.4 12.8 12.8 636 
(387 - 876) 





2017 2013 - 
2015 
PC 515 7.6 5.0 12.0 NR 713 
(561 - 958) 
NR NR NR 
Zanoni  
[48]  
2017 2007 - 
2015 












2016 2013 - 
2015 
PC 126 6.3 NR 15 NR NR NR 69% <400 
Davies  
[50] 
2009 1999 - 
2008 




3.6 NR NR NR NR 82% at 3 
years 
<400 
ART:antiretroviral therapy, IQR:interquartile range, VL:viral load, NR:not recorded, PC:prospective cohort, CS:cross-sectional, RC:retrospective cohort, PHIV:perinatally HIV-
infected 




Table 2: Studies reporting long-term growth in perinatally-HIV-infected adolescents 
Reference Year of 
public-
ation 




















at ART start 
(IQR) 
Median HAZ 




2017 South Africa 
 2013 - 2015 
LMIC PC 515 7.6 5.0 12.0 NR NR NR -1.3† 




2008 - 2014 
LMIC RC 103 NR (3 year 
outcomes 
reported) 
6.8 NR -1.18 
(1.61) 
-1.00 (1.11) 









2008 - 2014 
LMIC RC 534 3.6 11.8 NR NR NR -2.3 
(-3.6 to -1.4) 
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Background: The burden of paediatric HIV in South Africa has shifted to older children and 
adolescents. Nevertheless, information on long-term treatment outcomes of perinatally-HIV-
infected (PHIV) children is limited.  
Objectives: We examined long-term immunologic and virologic outcomes of children who 
were in care at least 10 years after starting antiretroviral therapy (ART).  
Methods: We performed a retrospective cohort study of 127 PHIV children who initiated ART 
at a Cape Town clinic between 2002 and 2005, and had follow-up for ≥ 10 years from ART 
initiation date. CD4 counts and viral loads (VL) were analysed for each successive year on ART. 
Treatment history, resistance test results, growth data, hospital admissions and opportunistic 
infection history were described. 
Results:  At ART initiation, median age was 2.6 years (IQR 1.3 – 4.9) and mean CD4 percentage 
was 13.7% (95% Confidence Interval [CI] 13.6 – 13.9). The first ART regimen was non-
nucleoside reverse transcriptase inhibitor-based (64%) or protease inhibitor-based (36%). 
Median follow-up was 12.2 years (interquartile range [IQR] 11.1 – 13.0). At the last 
assessment, 50% of patients were on 1st-line and 43% on 2nd-line ART. At the last assessment, 
median CD4 count was 686 cells/µl (IQR 545 – 859) and 79% had CD4 >500 cells/µl (92% of 
those on 1st-line vs 71% of those on 2nd-line ART; p=0.003). At the last assessment, 80% of 
patients were virally suppressed (VL <400 copies/ml) (86% of those on 1st-line vs 71% on 2nd-
line ART; p=0.183).The 10-year probability of experiencing viral failure was 56.7% (95% CI 48.3 
– 65.5%) and the 10 year probability of switching to 2nd-line ART was 45.7% (95% CI 37.5 -
54.8%). The probability of experiencing viral failure between the age of 10 and 18 was 37.4% 
(95% CI 25.4 – 52.8%). 
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Conclusions: Virologic and immunologic outcomes were good overall in PHIV children who 
remained in care for ≥10 years, but >40% of children were on 2nd-line ART with poorer 
immunologic outcomes. Maintaining virologic and immunologic control in adolescence 




There are currently an estimated 320 000 children under the age of 15 years living with 
Human Immunodeficiency Virus (HIV) in South Africa (SA).[1] Due to a combination of recent 
success in preventing new vertical infections and success of paediatric antiretroviral therapy 
(ART) programmes in improving life-expectancy in perinatally-HIV-infected (PHIV) children, 
the burden of paediatric HIV in SA has changed to older children, and this effect is projected 
to increase further by 2020.[2] There is an increasing population of PHIV children on ART 
reaching adolescence in SA’s health care system, yet information on long-term treatment 
outcomes in this unique group of highly treatment-experienced adolescents is very limited. 
Adolescence in general is a period characterised by physical, emotional and psychological 
change. It is associated with developing autonomy and sexuality, questioning authority, 
greater peer influence, increased impulsivity and risk taking.[3] Adolescents with HIV are at 
high risk of poor ART adherence, drug resistance and viral failure (VF). Barriers to adherence 
can include busy schedules (school and social), treatment fatigue, high pill burdens, complex 
twice-daily regimens, drug side-effects and disclosure issues.[3] In addition, socioeconomic 
difficulties related to orphanhood and stigma, as well as HIV-related behavioural and 




Many PHIV children are reaching adolescence and beyond, transitioning to adult care, yet 
healthcare systems are often lacking in preparedness to deal with the complex and evolving 
needs of PHIV children as they age into adolescence and young adulthood. In Africa, HIV 
services dedicated to young people and their needs are scarce[5] and when viral failure occurs, 
there are limited second- and third-line ART options available, particularly when protease 
inhibitors (PIs) have been used in the 1st-line regimen in children. While several studies have 
reported on viral and immunological outcomes in PHIV cohorts on ART, few have reported 
the outcomes after more than a decade of treatment.[6-11] Viral suppression ranged from 37 
– 68% and optimal immune status (CD4 count >500 cells/µl) ranged from 42 – 59% in these 
studies, which were all from high income countries. These studies may not be generalizable 
to low and middle income countries (LMIC), including SA, as many children in these cohorts 
were on the one hand exposed to older, less efficacious regimens in the 1990s, while on the 
other hand they were likely to have had access to a wider range of antiretrovirals and more 
tailor-made regimens than children in LMIC in the 2000s.  
 
There are no published data on outcomes in PHIV children in LMIC on ART for 10 years or 
longer. Although national paediatric ART programmes were implemented in South Africa over 
a decade ago, the long-term outcomes of PHIV children on ART have not yet been described. 
This study aimed to contribute to available knowledge by describing local outcomes, which 
can aid in anticipating future challenges and planning further management in treatment-
experienced adolescents and young adults. The main objective of the study was to describe 







We conducted a retrospective cohort study of PHIV adolescents on ART. Primary outcomes 
were annual viral load (VL) and CD4 results. Secondary outcomes were ART regimen history, 
resistance test results, height and weight measurements, history of opportunistic infections 
and hospital admissions. The study population consisted of PHIV adolescents and young 
adults attending the Adolescent Infectious Diseases Clinic at Groote Schuur Hospital (GSH) in 
Cape Town. This is a tertiary-level clinic in an urban setting. The paediatric ART programme 
was initially implemented in 2002 by a non-governmental organisation (Kidzpositive), and was 
taken over by the Department of Health during 2004. Approval for the research was obtained 
from the University of Cape Town’s Faculty of Health Sciences Human Research Ethics 
Committee (HREC Ref: 891/2015). 
 
Participants were identified from the clinic’s enrolment register and attendance database. 
Inclusion criteria were: (1) ART initiation at the GSH paediatric clinic or in the GSH paediatric 
ward (with follow-up at the clinic), (2) age <12 years at initiation (maximum age for referral 
to paediatric services; also serves as a proxy for perinatal route of infection), (3) ART initiation 
between 13 May 2002 (inception of the ART programme) and 31 December 2005, (4) 
attendance at the clinic for a minimum of 10 years since ART initiation date, including those 
who had previous gaps in care or had been transferred out but returned and were in care ≥10 
years after ART start, (5) previously ART-naïve, with the exception of possible nevirapine 
exposure as part of the prevention of mother-to-child transmission  programme implemented 
in the Western Cape from 1999 and (6) children who initiated care at the clinic as part of a 
clinical research study were included, provided that the study was a pharmacokinetic study 
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and not a study comparing the effectiveness of different antiretroviral treatments or other 
interventions. We excluded those who were not in care at the clinic at least 10 years after 
ART initiation, due to death, loss to follow-up (LTFU) or transfer of care to another institution.  
 
Clinical data was collected from the patients’ clinical records and laboratory results were 
obtained from the National Health Laboratory Service. Information was captured from the 
time of ART initiation until the censoring date when LTFU, death or transfer occurred or until 
the study ended on 31 December 2015 if still in active care. Data were compiled into Excel 
spreadsheets and uploaded to Stata version 14 for analysis. Kaplan-Meier survival analysis 
and Cox proportional hazard methods of analysis were applied to identify time to VF and 
factors associated with VF. Independent variables for inclusion in multivariable models were 
selected a priori. 
 
Viral suppression was regarded as VL <400 copies/ml. Viral failure was regarded as two 
sequential VL >1000 copies/ml that were >24 weeks since ART initiation, taken between 14-
365 days apart and not measured during a treatment interruption. Annual CD4 and VL was 
defined as the measure taken nearest to but within ± 6 months of the respective annual time 
points. World Health Organization (WHO) age-related classification of immunosuppression 
was used.[12] Optimal immune status was defined as CD4 >500 cells/µl in those >5 years old. 
Changing from 1st- to 2nd-line therapy was defined as changing at least 2 ART drugs in the 
regimen, one of which was a class switch from non-nucleoside reverse transcriptase inhibitor 
(NNRTI) to PI, or PI to NNRTI, where the reason for changing drugs was due to VF, was not 
due to toxicity and the child was not virally suppressed at the time of switch. Genotypic drug 
resistance was defined as intermediate- or high-level resistance. LTFU was defined as no visit 
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for >6 months before database closure in a child not known to have transferred out or died. 
WHO child growth standards were used to calculate Z-scores.[13] 
 
4. Results  
 
4.1 Cohort characteristics 
 
Between May 2002 and December 2005, 349 children enrolled for ART initiation. Prior to 
reaching 10 years of follow-up, 29 (8%) died, 33 (9%) were LTFU, 150 (43%) were transferred 
to other facilities (with no transfer back to GSH) and 10 (3%) had missing records. The 
remaining 127 (36%) remained in care for ≥10 years and formed the study cohort. At ART 
initiation, the median age of the 127 children included in the study was 31 (interquartile range 
(IQR) 16 – 58) months and median CD4% was 13% (IQR 9 - 18), with 63% of the children 
classified as severely immune suppressed. ART was started as in-patients in 12 (9%) of the 
children. Children were followed up for a median of 12. 2 (IQR 11.1 – 12.9) years, with a mean 
number of 6 clinic visits per year. Among the cohort, 26 (20%) had transferred care to other 
facilities and subsequently transferred back again, predominantly for adolescent support. In 
the study period following 10 years since ART initiation, 1 patient died, 2 were LTFU and 19 
(15%) transferred to other clinics. Participants’ ages ranged from 10 – 22 years at study close. 




Table 1: Characteristics of 127 children at antiretroviral therapy start and at last assessment 
Characteristic 
 
At ART start At last assessment 
Sex (n; %) Male 62 (48.8) 
 
 
Female 65 (51.2) 
 
Age (median; IQR) Years 2.6 (1.3 - 4.9) 15.1 (13 - 17.7) 
Age category (n; %) <1 year 23 (18) 
 
 
1 - 4 years 73 (58) 
 
 
5 - 9 years 26 (20) 
 
 




Year of ART start (n; %) 2002 33 (26) 
 
 
2003 52 (41) 
 
 
2004 23 (18) 
 
 
2005 19 (15) 
 
Previous exposure to PMTCT Known exposed 9 (7.1) 
 
(n; %) Known unexposed 32 (25.2) 
 
 
Unknown 86 (67.7) 
 
CD4 % by age category (median; IQR) <1 year 9.7 (6.9 - 17.0) 
 
(n=121 at ART start) 1 - 9 years 14.0 (10.0 – 18.0) 
 
 
10 - 14 years 9.0 (7.0-22.7) 30.5 (27.0 - 36.9)  
≥15 years 
 
27.9 (21.2 - 33.5) 
CD4 absolute count (median; IQR) (n=122 at ART start) 502 (275-813) 686 (545 - 859) 
Immune suppression category* (n; %) None 13 (10.7) 100 (78.7) 
(n=121 at ART start) Mild  8 (6.6) 12 (9.4)  
Advanced 24 (19.8) 10 (7.9)  
Severe 76 (62.8) 5 (4) 
VL >1 million copies/ml (n; %) (n=80) 
 
14 (17.5) 0 
VL <400 copies/ml (n; %) 
 
n/a 101 (79.5) 
WAZ (median; IQR) (n=115) Overall -1.97 (-3.23 to -0.66) 
 
WAZ category (n; %) ≥-2 58 (50.4) 
 
 
<-2 57 (49.6) 
 
HAZ (median; IQR) (n=113) Overall -2.92 (-4.09 to -1.95) -1.52 (-2.22 to -0.79) 
HAZ category (n; %) ≥-2 31 (27.4) 87 (68.5)  
<-2 82 (72.6) 40 (31.5) 
BAZ (median; IQR) (n=113 at ART start) Overall 0.2 (-0.78 - 1.25) -0.16 (-1.04 - 0.56) 
BAZ category (n; %) ≥-2 98 (86.7) 120 (94.5)  
<-2 15 (13.3) 7 (5.5) 
c-ART regimen (n; %) NVP + 2 NRTIs 78 (61.4) 12 (10) 
(n=120 at last assessment) LPV/rtv + 2 NRTIs 34 (26.8) 63 (52.5)  
rtv + 2 NRTIs 12 (9.5) -  
EFV + 2 NRTIs 3 (2.4) 21 (17.5)  
ATAZ/rtv + 2 NRTIs 0 17 (14.2)  
Other 0 7 (5.8) 
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All children were included unless n is specified. ART:antiretroviral therapy, IQR:interquartile range, 
PMTCT:prevention of mother-to-child transmission, VL:viral load, WAZ:weight for age Z-score, HAZ:height for age Z-
score, BAZ:body mass index for age Z-score, c-ART:combination ART, NVP:nevirapine, NRTI: nucleoside reverse 
transcriptase inhibitor, EFV:efavirenz, LPV:lopinavir, rtv:ritonavir, ATAZ:atazanavir 
*Immunodeficiency categories: None if <11 months and CD4>35%, 12-35 months and >30%, 36-59 months and 
>25%, >5 years and >500 cells/µl; Mild if <11 months and 30-35%, 12-35 months and 25-30%, 36-59 months and 20-
25%, >5 years and 350-499 cells/µl; Advanced if <11 months and 25-29%, 12-35 months and 20-24%, 36-59 months 
and 15-19%, >5 years and 200-349 cells/µl; Severe if <11 months and <25%, 12-35 months and<20%, 36-59 months 




Figure 1: Flow diagram of cohort progression to viral suppression and viral failure (VF) since 
antiretroviral therapy (ART) initiation  
 
 
4.2 Treatment history 
 
At ART initiation 64% of children were on NNRTI-based and 36% on PI-based regimens. Over 
time, there were 91 instances of documented patient- or caregiver-initiated treatment 
interruptions, which occurred in 40 (31%) patients. Drug switches due to lipodystrophy were 
made in the regimens of 64 (50%) patients at a median age of 11 years, mostly attributable 
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to stavudine but also zidovudine and didanosine. At the last assessment, 50% of patients were 
on 1st-line ART, 43% were on 2nd-line ART, 3% on salvage- or mono-therapy and 4% on no ART. 
Among those on combination-ART, 28% were on NNRTI-based and 72% on PI-based regimens. 
One patient was using an integrase inhibitor. 
 
4.3 Virologic outcomes 
 
After ART initiation, 76% of children initially had viral suppression and 41% maintained good 
virologic control, never experiencing VF throughout follow-up (Figure 1). Two children never 
experienced viral suppression throughout follow-up. 
 
The Kaplan-Meier 10 year probability of experiencing VF was 56.7% (95% CI 48.3 – 65.5). 
Among those that experienced VF (75/127; 59%), VF occurred at a median age of 4 years (IQR 
2.9 – 8.5) and median duration on ART of 1.5 years (IQR 1.1 – 2.7). The 10 year probability of 
switching to 2nd-line ART was 45.7% (95% CI 37.5 -54.8). Factors associated with first episode 
of VF were analysed by Cox proportional hazards modelling (Table 2A). Female sex was 
independently associated with a 0.44 times lower hazard of developing VF (95% CI: 0.23 – 
0.85). Use of suspensions in the ART regimen, compared with use of tablets only, was 
associated with a 3.48 times increased hazard of VF (95% CI: 1.13 – 10.75). 
  
At the last assessment, 80% of the cohort were virally suppressed (86% on 1st-line vs 77% on 
2nd-line; p=0.183). There was no significant difference in the proportion virally suppressed on 
NNRTI- vs PI-based regimens (89% vs 78%; p=0.169), by age 10 – 14 vs ≥ 15 years at last 
assessment (83% vs 75%; p=0.224) or by history of previous exposure to single-PI ritonavir vs 
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not (72% vs 81%; p=0.41). The Kaplan-Meier probability of experiencing VF between the age 
of 10 and 18 was 37.4% (95% CI 25.4 – 52.8%). VF occurred at a constant rate throughout 
adolescence (Figure 2A). Advanced immunodeficiency (CD4 <350 cells/µl) at age 10 was 
independently associated with a 4.05 times increased hazard of developing VF during 
adolescence (95% CI: 1.04 – 15.82). In addition, having a history of previous VF before the age 
of 10 was independently associated with a 3.20 times increased hazard of developing VF after 
the age of 10 (95% CI 1.05 – 9.74). The proportion of patients virally suppressed at each year 
since ART initiation increased gradually until 8 years since ART initiation and thereafter 
decreased (Figure 2B). 
 
Ten percent of the cohort had drug resistance documented, which was found in 13 out of the 
16 children tested. Of these, 2 had nucleoside reverse transcriptase inhibitor (NRTI) 
resistance, 2 had NNRTI resistance, 7 had both NNRTI and NRTI resistance and 2 had both PI 
and NRTI resistance.  
 
4.4 Immunologic outcomes 
 
At the last assessment, 4% of the cohort had CD4 <200 cells/µl and 79% had CD4 >500 cells/µl. 
Patients on 1st-line ART at last assessment were more likely to have CD4 >500 cells/ µl vs those 
on 2nd-line, (92% vs 71%; p=0.003). Similarly, those on NNRTI-based regimens were more 
likely to have CD4 >500 cells/µl vs those on PI-based regimens (94% vs 77%; p=0.003). 
Stratified by age 10 – 14 vs ≥ 15 years at last assessment, 92% vs 62% (p<0.001) had CD4 >500 
cells/µl. The percentage of patients with optimal immunologic status at each year since ART 






At ART initiation, median height-for-age Z-score (HAZ) was -2.92 (IQR -4.09 to -1.95) and 73% 
of the children were growth stunted (HAZ <-2). At the last assessment, median HAZ was -1.52 
(IQR -2.22 to -0.79) and 32% were growth stunted. Although HAZ improved over time, it 
remained below WHO standards (Figure 2D and 2E). 
 
4.6 Clinical outcomes 
 
The number of hospital admissions was highest in the first year after ART initiation, and 
decreased thereafter (Table 3A). The most common reasons for admissions were lower 
respiratory tract infections (46%) and pulmonary tuberculosis (TB) (10%). The incidence of TB 
was high: 53 episodes of TB were diagnosed in 51 patients (40% of the cohort) after >4 weeks 
since ART initiation (Table 3B). Among those who developed TB >24 weeks since ART 
initiation, 56% were not virally suppressed at the most recent assessment. Chronic lung 










Table 2: Factors associated with (A) first episode of viral failure and (B) viral failure after 
the age of 10, from multivariate Cox modelling 
 
(A) Factor associated with first VF Adjusted HR 95% CI p-value 
 Sex male 1   
  female 0.44 0.23 - 0.85 0.014 
 Type of regimen NNRTI-based 1   
  PI-based 0.62 0.20 - 1.98 0.423 
 Current age  (years) 1.05 0.89 - 1.24 0.568 
 Programme year 2002 1   
  2003 0.87 0.41 - 1.84 0.709 
  2004 0.94 0.19 - 4.79 0.943 
  2005 0.24 0.05 - 1.18 0.079 
 Severe immune suppression at ART start 1.42 0.63 - 3.23 0.400 
 VL > 1 million at ART start  1.45 0.62 - 3.37 0.391 
 Drug formulations tablets only 1   
  use of suspensions 3.48 1.13 - 10.75 0.030 
(B) 
 
Factor associated with VF after age 10* Adjusted HR 95% CI p-value 
 Sex male 1   
  female 1.44 0.64 - 3.24 0.378 
 Type of regimen NNRTI-based 1   
  PI-based 0.75 0.25 - 2.27 0.612 
 Age at ART start (years) 1.11 0.93 - 1.32 0.232 
 Programme year 2002 1   
  2003 1.52 0.54 - 4.25 0.428 
  2004 1.51 0.37 - 6.07 0.563 
  2005 2.2 0.41 - 11.98 0.360 
 Previous VF <10 years old  3.2 1.05 - 9.75 0.040 
 








*10 children with VF at age 10 were excluded from analysis  
 VF:viral failure, HR:hazard ratio, NNRTI:non-nucleoside reverse-transcriptase inhibitor, PI:protease inhibitor,  





Figure 2A: Kaplan Meier probability of viral failure after age 10 years 
 
 
Figure 2B: Percentage of patients virally suppressed at each year since antiretroviral 
therapy initiation 
 


































Figure 2C: Percentage of patients with optimal immunologic status* at each year since 
antiretroviral therapy (*classified as age <11 months and CD4>35%, age 12-35 months and 
>30%, age 36-59 months and >25%, age >5 years and >500 cells/µl) 
 
 

























































Figure 2E: Mean height-for-age Z-score (HAZ) by time since antiretroviral therapy initiation 
 
 
Table 3: Clinical outcomes of 127 children on antiretroviral therapy: (A) hospital 
admissions and (B) tuberculosis incidence 
 
 





admissions (n; %) 
Most common reasons for 
admission 
 
<1 92 53 (42) LRTI (51%) GE (8%) LRTI and GE 
(8%) Septicaemia (8%) PTB (5%)  
≥1 and <5 67 43 (34) LRTI (40%) PTB (16%) GE (9%) 
Septicaemia (6%)  
≥5 and <10 42 24 (19) LRTI (45%) Measles (19%) GE (7%)  
≥10 and <15 20 14 (11) LRTI (40%) PTB (20%) Appendicitis 
(10%) Epilepsy (10%)      





% not virally 
suppressed at TB 
diagnosis 
% with advanced  or severe 
immune suppression 
 
On TB treatment at ART 
start or < 4 weeks of ART 
start 
15 (12) n/a 86% 
 
≥ 4 weeks and ≤ 24 weeks 4 (3) n/a 100%  
> 24 weeks and ≤ 1 year 5 (4) 40% 50%  
> 1 year and ≤ 5 years 23 (18) 58% 25%  
> 5 years ≤ 10 years 12 (9) 64% 14%  
> 10 years 9 (7) 44% 44% 
ART:antiretroviral therapy, LRTI:lower respiratory tract infection, GE:gastroenteritis, PTB:pulmonary 























To our knowledge, this is the first published study of outcomes after more than ten years in 
HIV care of PHIV children in South Africa. After median follow-up of 12 years on ART, 80% of 
this cohort were virally suppressed and 79% had optimal immune status. These results 
compare favourably with studies in high income countries.[6-11] However, these PHIV 
adolescents comprise a vulnerable group, with impaired growth outcomes and ongoing 
burden of clinical disease. Maintaining virologic control and optimal immune status in 
adolescence may be challenging. A high proportion of patients have already had at least one 
episode of confirmed VF before adolescence and approximately one in three children 
experience new confirmed VF between age 10 and 18 years.  
 
Both immunologic and virologic outcomes initially improved substantially after ART initiation 
in this group, but appeared to deteriorate about 10 years after ART start. Understanding the 
reason for these deteriorating outcomes is crucial to developing targeted interventions to 
address them. In this respect, VF occurred at a constant rate after age 10 years, similar to 
results in Asian adolescents.[14]. Entering adolescence with CD4 <350 cells/µl or with a history 
of previous viral failure were predictors of experiencing new VF during adolescence. In 
addition, it was notable that adolescents >15 years, those on 2nd-line therapy and those on 
PI-based therapy were more likely to have CD4 <500 cells/µl. 
 
Across the entire follow-up period, we found an increased hazard of VF in children using 
suspensions. This is not surprising as some suspensions are unpalatable, giving accurate doses 
is more difficult compared to tablets, especially if a child vomits or spits out the medicine, and 
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frequent weight-based dosage changes are needed as the child grows, with risk of errors (by 
clinicians or caregivers). Optimising drug formulations across the paediatric age range may 
reduce the risk of VF and drug resistance, facilitating better adolescent outcomes. Resistance 
testing is not routinely performed in SA when changing from an NNRTI-based regimen due to 
VF, nor is it routinely performed when VF occurs in patients on a PI-based regimen if ongoing 
poor adherence is observed. The true incidence of resistance is therefore likely to be higher 
than the 10% documented.  
 
The high burden of stunting, hospitalisation and clinical disease, especially TB, despite several 
years on ART in our cohort, is notable. The majority of incident TB cases occurred in patients 
who were not virally suppressed. This is consistent with findings in adult studies that HIV-
infected patients with high VL are at high risk of TB, irrespective of CD4 counts.[15-16] One in 
four children in our cohort had chronic lung disease, a well-known complication among PHIV 
adolescents, particularly in sub-Saharan Africa.[17-18] Despite HAZ improvements in childhood, 
in this study and others in LMIC,[19-20] PHIV adolescents continue to be at least one standard 
deviation below normal height, with potential impact on final adult height. 
  
This is one of the first studies with >10 years of follow-up of PHIV adolescents from sub-
Saharan Africa. Strengths of our study include the detailed long-term individual trajectories, 
including viral load and clinical outcomes, and that the study reflects the real-world rather 
than trial settings. The extended time frame allowed for inclusion of patients who had 
previous gaps in care or transfer out and who at an earlier stage would have been considered 
LTFU or transferred to another site. Limitations of the study include the small sample size, the 
retrospective study design, and that the data comes from a single study site in a tertiary care 
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institution. Since we focused on children on ART for at least 10 years at the same site, there 
is survival bias in this cohort. Nevertheless, it is precisely this surviving group of PHIV 
adolescents that needs to be described in order to optimize management during adolescence 
and transition to adulthood.  
 
There may be reduced external validity due to this being a tertiary care cohort. Within SA and 
sub-Saharan Africa more broadly the model of retaining children at a separate paediatric 
tertiary facility is unusual. In addition, there is selection bias in the current cohort of children 
with ≥10 years of follow up as many were long-term survivors and regular clinic attendees 
during the era before ART was widely available.  Subsequent cohorts of adolescents will have 
had the advantage of starting ART before the onset of severe disease. The children in this 
study benefitted from tertiary-level support available at the clinic (psychologists, social 
workers, counsellors and peer support groups), so results from the study may not be 
generalizable to children treated at primary care level where HIV services dedicated to young 
people and their needs are often lacking. Some variables that may be related to the risk of 
developing VF, for example caregiver factors, disclosure, depression and neurocognitive 




The long-term virologic and immunologic outcomes were good overall in PHIV children 
remaining in care for ≥10 years. However, a worsening trend was observed in adolescence, 
which may be reflective of growing autonomy and worse adherence during adolescence. 
Given their long-term treatment histories including prior viral failure and ongoing clinical 
73 
 
disease burden, these adolescents will require careful management as they transition to adult 
care and beyond. There is a need for similar studies of long-term outcomes in PHIV children 
at other sites in South Africa, particularly in primary care settings, as well as further studies 
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PART D: APPENDICES 
 







Appendix 2: Data collection sheets  
 
 
PATIENT (UNIQUE AND ANONYMOUS CODE TO IDENTIFY 
COHORT PATIENT) 












(DRUG NAME AND DURATION 
or “NONE” 


















(IF PERFORMED: DATE, RESULT, 
RECOMMENDATIONS. 











PATIENT (CODE) -LINE 
ART_ID  
 




(DATE OF DRUG START)  
ART_ED  
(dd-mm-yyyy) 
(DATE OF DRUG STOP)  










































DATE (dd-mm-yyyy) CD4 COUNT - ABS CD4 % 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   









DATE (dd-mm-yyyy) VIRAL LOAD - COUNT LOG VALUE 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   









CLINIC VISIT DATE  
(dd-mm-yyyy) 
HEIGHT (cm) WEIGHT (kg) 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   












(YES OR NO) 
IF YES,  
DURATION 
(DAYS) 
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Age-related CD4 values 
<11 months 
(CD4%) 
12 – 35 
months 
(CD4%) 







None or not significant >35 >30 >25 >500 
Mild 30 - 35 25 - 30 20-25 350 - 499 
Advanced 25 - 29 20 - 24 15 - 19 200 - 349 
Severe <25 <20 <15 <200 or 
<15% 
 
Appendix 4: Table of opportunistic infections for data capturing of clinical outcomes 
 
Stage 3 and 4 opportunistic infections of HIV, adapted from WHO clinical staging of HIV 
disease in adults, adolescents and children (2013): 
Unexplained persistent diarrhoea (≥14 days in children; >1 month in adults/adolescents) 
Persistent oral candidiasis 
Lymph node tuberculosis  
Pulmonary tuberculosis  
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
Symptomatic lymphoid interstitial pneumonitis 
Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint 
infection, meningitis, bacteraemia) 
Pneumocystis (jirovecii) pneumonia 




Central nervous system toxoplasmosis 
Extrapulmonary cryptococcosis, including meningitis  
Disseminated nontuberculous mycobacterial infection 
Chronic cryptosporidiosis  
Chronic isosporiasis 
Disseminated mycosis (extrapulmonary histoplasmosis, coccidioidomycosis) 
Recurrent septicaemia (including nontyphoidal Salmonella) 






Appendix 5: Author guidelines for the South African Medical Journal 
 
Research 
Guideline word limit: 4 000 words 
  
Research articles describe the background, methods, results and conclusions of an original research study. 
The article should contain the following sections: introduction, methods, results, discussion and conclusion, 
and should include a structured abstract (see below). The introduction should be concise – no more than 
three paragraphs – on the background to the research question, and must include references to other 
relevant published studies that clearly lay out the rationale for conducting the study. Some common reasons 
for conducting a study are: to fill a gap in the literature, a logical extension of previous work, or to answer an 
important clinical question. If other papers related to the same study have been published previously, please 
make sure to refer to them specifically. Describe the study methods in as much detail as possible so that 
others would be able to replicate the study should they need to. Results should describe the study sample as 
well as the findings from the study itself, but all interpretation of findings must be kept in the discussion 
section, which should consider primary outcomes first before any secondary or tertiary findings or post-hoc 
analyses. The conclusion should briefly summarise the main message of the paper and provide 
recommendations for further study. Select figures and tables for your paper carefully and sparingly. Use only 
those figures that provided added value to the paper, over and above what is written in the text. Do not 
replicate data in tables and in text. 
  
Structured abstract 
 This should be 250-400 words, with the following recommended headings: 
o Background: why the study is being done and how it relates to other published work. 
o Objectives: what the study intends to find out 
o Methods: must include study design, number of participants, description of the intervention, primary and 
secondary outcomes, any specific analyses that were done on the data. 
o Results: first sentence must be brief population and sample description; outline the results according to the 
methods described. Primary outcomes must be described first, even if they are not the most significant 
findings of the study. 
o Conclusion: must be supported by the data, include recommendations for further study/actions. 
 Please ensure that the structured abstract is complete, accurate and clear and has been approved by all 
authors. 
 Do not include any references in the abstracts.  
Main article 
 
All articles are to include the following main sections: Introduction/Background, Methods, Results, 
Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
 Objectives (within Introduction/Background): a clear statement of the main aim of the study and the major 
hypothesis tested or research question posed 
 Design (within Methods): including factors such as prospective, randomisation, blinding, placebo control, case 
control, crossover, criterion standards for diagnostic tests, etc. 
 Setting (within Methods): level of care, e.g. primary, secondary, number of participating centres. 
 Participants (instead of patients or subjects; within Methods): numbers entering and completing the study, 
sex, age and any other biological, behavioural, social or cultural factors (e.g. smoking status, socioeconomic 
group, educational attainment, co-existing disease indicators, etc)that may have an impact on the study 
results. Clearly define how participants were enrolled, and describe selection and exclusion criteria. 
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 Interventions (within Methods): what, how, when and for how long. Typically for randomised controlled trials, 
crossover trials, and before and after studies. 
 Main outcome measures (within Methods): those as planned in the protocol, and those ultimately measured. 
Explain differences, if any. 
Results 
 Start with description of the population and sample. Include key characteristics of comparison groups. 
 Main results with (for quantitative studies) 95% confidence intervals and, where appropriate, the exact level of 
statistical significance and the number need to treat/harm. Whenever possible, state absolute rather than 
relative risks. 
 Do not replicate data in tables and in text. 
 If presenting mean and standard deviations, specify this clearly. Our house style is to present this as follows: 
 E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for mean (SD). 




Please ensure that the discussion is concise and follows this overall structure – sub-headings are not needed: 
 Statement of principal findings 
 Strengths and weaknesses of the study 
 Contribution to the body of knowledge 
 Strengths and weaknesses in relation to other studies 
 The meaning of the study – e.g. what this study means to clinicians and policymakers 
 Unanswered questions and recommendations for future research 
Conclusions 
 
This may be the only section readers look at, therefore write it carefully. Include primary conclusions and 




NB: Only complete, correctly formatted reference lists in Vancouver style will be accepted. Reference lists 
must be generated manually and not with the use of reference manager software. Endnotes must not be 
used. 
 Authors must verify references from original sources. 
 Citations should be inserted in the text as superscript numbers between square brackets, e.g. These 
regulations are endorsed by the World Health Organization,[2] and others.[3,4-6] 
 All references should be listed at the end of the article in numerical order of appearance in the Vancouver style 
(not alphabetical order). 
 Approved abbreviations of journal titles must be used; see the List of Journals in Index Medicus. 
 Names and initials of all authors should be given; if there are more than six authors, the first three names 
should be given followed by et al. 
 Volume and issue numbers should be given. 
 First and last page, in full, should be given e.g.: 1215-1217 not 1215-17. 
 Wherever possible, references must be accompanied by a digital object identifier (DOI) link). Authors are 
encouraged to use the DOI lookup service offered by CrossRef: 
o On the Crossref homepage, paste the article title into the ‘Metadata search’ box. 
o Look for the correct, matching article in the list of results. 
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o Click Actions > Cite 
o Alongside 'url =' copy the URL between { }. 
o Provide as follows, e.g.: https://doi.org/10.7196/07294.937.98x 
Some examples: 
 Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about glaucoma. Stat Med 
1998;289(1):350-355. http://dx.doi.org/10.1000/hgjr.182 
 Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 1975:96-101. 
 Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic Properties of Invading Microorganisms. In: 
Sodeman WA, Sodeman WA, eds. Pathologic Physiology: Mechanisms of Disease. Philadelphia: WB Saunders, 
1974:457-472. 
 Internet references: World Health Organization. The World Health Report 2002 - Reducing Risks, Promoting 
Healthy Life. Geneva: WHO, 2002. http://www.who.int/whr/2002 (accessed 16 January 2010). 
 
 
 
